Journal of Neurology

, Volume 259, Issue 2, pp 284–291 | Cite as

Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study

  • Thomas Meier
  • Susan L. Perlman
  • Christian Rummey
  • Nicholas J. Coppard
  • David R. Lynch
Original Communication


The aim of this study was to investigate the efficacy of idebenone on neurological function as assessed by ICARS and FARS neurological rating scales in pediatric Friedreich's ataxia (FRDA) patients. Sixty-eight pediatric patients were enrolled in an open-label extension study (IONIA-E) where patients received idebenone (Catena®, 150 mg film-coated tablets) at a weight-adjusted dose of 1,350/2,250 mg/day for 12 months after patients had completed a double-blind, randomized, placebo-controlled study (IONIA) receiving either idebenone at a weight-adjusted dose of 450/900 or 1,350/2,250 mg/day or placebo for 6 months. Changes in ICARS and FARS total scores and subscores were recorded for the 12-month IONIA-E study and for the 18-month combined IONIA and IONIA-E study period. Data analyzed by a mixed-model repeated-measures ANCOVA relative to baseline resulted in least square means for the change in ICARS for the IONIA-E study of +0.98 points (SEM 0.73; p = 0.180), indicating a trend for worsening. However, combined with the IONIA study the change was −1.03 ± 0.68 points (p = 0.132), indicating a trend for improvement in neurological function over the 18-month period. Importantly, patients who received idebenone 1,350/2,250 mg/day over this period significantly improved in neurological function (change in ICARS: −3.02 ± 1.22, p = 0.014). The improvement in neurological function over time was best seen when the posture and stance subscore was excluded from the analysis. Comparable data were obtained with the FARS. The findings of the open-label IONIA-E study combined with the double-blind IONIA study indicate that idebenone at a dose of 1,350/2,250 mg/day may offer a therapeutic benefit to pediatric FRDA patients by stabilizing the overall neurological function and improving fine motor skills and speech.


Ataxia International Cooperative Ataxia Rating Scale Idebenone Movement disorder 

Supplementary material

415_2011_6174_MOESM1_ESM.doc (36 kb)
Supplementary material 1 (DOC 36 kb)


  1. 1.
    Klockgether T, Lüdtke R, Kramer B et al (1998) The natural history of degenerative ataxia: a retrospective study in 446 patients. Brain 121:589–600PubMedCrossRefGoogle Scholar
  2. 2.
    Durr A, Cossee M, Agid Y et al (1996) Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med 335:1169–1175PubMedCrossRefGoogle Scholar
  3. 3.
    Schulz JB, Boesch S, Bürk K et al (2009) Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat Rev Neurol 5:222–234PubMedCrossRefGoogle Scholar
  4. 4.
    Harding AE (1981) Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and interfamilial clustering of clinical features. Brain 104:589–620PubMedCrossRefGoogle Scholar
  5. 5.
    Tsou AY, Paulsen EK, Lagedrost SJ et al (2011) Mortality in Friedreich ataxia. J Neurol Sci (in press)Google Scholar
  6. 6.
    Santos R, Lefevre S, Sliwa D et al (2010) Friedreich ataxia: molecular mechanism, redox considerations, and therapeutic opportunities. Antiox Redox Signal 13:651–690CrossRefGoogle Scholar
  7. 7.
    Tonon C, Lodi R (2008) Idebenone in Friedreich’s ataxia. Expert Opin Pharmacother 9:2327–2337PubMedCrossRefGoogle Scholar
  8. 8.
    Schulz JB, Di Prospero NA, Fischbeck K (2009) Clinical experience with high dose idebenone in Friedreich ataxia. J Neurol 256(Suppl 1):42–45PubMedCrossRefGoogle Scholar
  9. 9.
    Di Prospero NA, Baker A, Jeffries N et al (2007) Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomized, placebo-controlled trial. Lancet Neurol 6(10):878–886PubMedCrossRefGoogle Scholar
  10. 10.
    Artuch R, Aracil A, Mas A et al (2002) Friedreich’s ataxia: idebenone treatment in early stage patients. Neuropediatrics 33(4):190–193PubMedCrossRefGoogle Scholar
  11. 11.
    Arnold P, Boulat O, Maire R et al (2006) Expanding view of phenotype and oxidative stress in Friedreich’s ataxia patients with and without idebenone. Schweizer Archiv für Neurology und Psychiatrie 157:169–176Google Scholar
  12. 12.
    Pineda M, Arpa J, Montero R et al (2008) Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long-term follow-up. Eur J Paediatr Neurol 12(6):470–475PubMedCrossRefGoogle Scholar
  13. 13.
    Lynch DR, Perlman SL, Meier T (2010) A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich Ataxia. Arch Neurol 67(8):941–947PubMedCrossRefGoogle Scholar
  14. 14.
    Trouillas P, Takayanagi T, Hallett M et al (1997) International cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. J Neurol Sci 145:205–211PubMedCrossRefGoogle Scholar
  15. 15.
    Subramony SH, May W, Lynch D et al (2005) Measuring Friedreich ataxia: interrater reliability of a neurologic rating scale. Neurology 64:1261–1262PubMedCrossRefGoogle Scholar
  16. 16.
    Folker J, Murdoch B, Cahill L et al (2010) Dysarthria in Friedreich’s ataxia: a perceptual analysis. Folia Phoniatr Logop 62:97–103PubMedCrossRefGoogle Scholar
  17. 17.
    Singh A, Epstein E, Myers LM et al (2010) Clinical measures of dysarthria in Friedreich ataxia. Mov Disord 25:108–121PubMedGoogle Scholar
  18. 18.
    Fahey MC, Corben L, Collins V et al (2007) How is disease progress in Friedreich’s ataxia best measured? A study of four rating scales. J Neurol Neurosurg Psychiatry 78:411–413PubMedCrossRefGoogle Scholar
  19. 19.
    Ribai P, Pousset F, Tanguy ML et al (2007) Neurological, cardiological, and oculomotor progression in 104 patients with Friedreich ataxia during long-term follow-up. Arch Neurol 64:558–564PubMedCrossRefGoogle Scholar
  20. 20.
    Sival DA, Brunt ER (2009) The international cooperative Ataxia Rating Scale shows strong age-dependency in children. Dev Med Child Neurol 51:571–572PubMedCrossRefGoogle Scholar
  21. 21.
    Friedman LS, Farmer JM, Perlman S et al (2010) Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord 25:426–432PubMedCrossRefGoogle Scholar
  22. 22.
    Di Prospero NA, Sumner CJ, Penzak SR et al (2007) Safety, tolerability, and pharmacokinetics of high-dose idebenone in patients with Friedreich ataxia. Arch Neurol 64:803–808PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Thomas Meier
    • 1
  • Susan L. Perlman
    • 2
  • Christian Rummey
    • 1
  • Nicholas J. Coppard
    • 1
  • David R. Lynch
    • 3
  1. 1.Santhera PharmaceuticalsLiestalSwitzerland
  2. 2.Department of NeurologyDavid Geffen School of Medicine at the University of California at Los AngelesLos AngelesUSA
  3. 3.Division of NeurologyThe Children’s Hospital of PhiladelphiaPhiladelphiaUSA

Personalised recommendations